In this webinar by CN Bio , Oliver Culley will explore how liver-on-a-chip technology enables researchers to delineate oligonucleotide distribution, uptake, and dosing to bridge the gap between preclinical studies and clinical success. Register now: https://bit.ly/41KK0Ie
Drug Discovery News
图书期刊出版业
Wilmington ，Delaware 8,188 位关注者
Exploring drug discovery and development
关于我们
Drug Discovery News provides engaging stories about scientific breakthroughs that will help life science researchers develop diagnostic and therapeutic approaches for improving human health. Read the latest drug development news at drugdiscoverynews.com.
- 网站
-
https://drugdiscoverynews.com/
Drug Discovery News的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 11-50 人
- 总部
- Wilmington ，Delaware
- 类型
- 私人持股
- 创立
- 2005
- 领域
- drug discovery and development、life science research、pharmaceuticals、biotechnology、publishing、clinical trials、biopharmaceuticals、diagnostics、biomarkers、cancer research、journalism、translational research和preclinical research
地点
-
主要
获取路线
1000 N West Street, Suite 1200
US，Delaware，Wilmington ，19801
Drug Discovery News员工
-
Cliff Dominy PhD
Medical Writer * Science Communicator * Translator of peer-reviewed literature * Journalist, lecturer & tutor for all things molecular.
-
Rajesh Kumar
News Editor/ Reporter at DDNews
-
Hannah Thomasy
Fellowship in Global Journalism at Dalla Lana School of Public Health, University of Toronto
-
Nidhi kumar
Celebrity show host on Indias public broadcaster at DD NEWS and DD NATIONAL, Ministry of Science, and Technology, Media lead and ambassador at Mitron…
动态
-
Shai Bel and his colleagues at Bar-Ilan University revealed that antibiotics led to the disappearance of the protective mucus layer in the guts of mice. It could be why antibiotics are linked to an increased risk of inflammatory bowel disease. Read more: https://bit.ly/4hvrKrc
-
-
CGRP inhibitors do not work for around 20 to 30 percent of patients with migraines. Johan Luthman and his colleagues at Lundbeck are developing a new treatment in a Phase 2 clinical trial that targets a different neuropeptide to hopefully provide relief to more people. Read more: https://bit.ly/3Qzuad1
-
-
Scientists are developing new techniques to determine antimicrobial susceptibility faster and with less hands-on time for clinical microbiologists, ultimately leading to better care for people with serious bacterial infection. Read more: https://bit.ly/412VGV9
-
-
In DDN’s Weekly Rundown, we covered the removal of mRNA-related language from grants, the latest updates on H5N1 research, positive results from a T cell immunotherapy, and more! Read about this week’s top drug discovery news here: https://bit.ly/4j0L3Kb
-
-
Serotonin decreases in the cerebellum during anxiety, opposite to other brain regions. Could the "little brain" become a novel target for future anti-anxiety treatments? Read more: https://bit.ly/3RgOTTg
-
-
Scientists are leveraging phages to deliver CRISPR-based gene-editing tools to modulate harmful microbes without eradicating them. This approach offers precision treatments for conditions like acne and gut infections while preserving microbiome balance. Read more: https://bit.ly/4iClCOX
-
-
The FDA recently approved the first non-opioid pain medication developed by Vertex Pharmaceuticals. “It's really exciting for the field. We haven't had a win in a very long time,” Ted Price told Allison Whitten. Read more about the new drug in this story: https://bit.ly/42ckdce
-
-
Judy Sebolt-Leopold at University of Michigan and her team at MEKanistic Therapeutics have pioneered the first dual-hit kinase inhibitor to treat cancers. Read more about their exciting discovery and future plans: https://bit.ly/4iwdzDn
-
-
An ancient Cas12a enzyme reconstructed from a three-billion-year-old bacterium widens gene editing capabilities to even more regions of the genome. Read more: https://bit.ly/3XVq2Ir
-